Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Other financing activities (2022 - 2026)

Oramed Pharmaceuticals filings provide 4 years of Other financing activities readings, the most recent being $2.3 million for Q4 2025.

  • Quarterly Other financing activities rose 87.83% to $2.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.0 million through Dec 2025, up 49.87% year-over-year, with the annual reading at $6.0 million for FY2025, 49.87% up from the prior year.
  • Other financing activities hit $2.3 million in Q4 2025 for Oramed Pharmaceuticals, up from $719000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $6.7 million in Q4 2023 and bottomed at -$1.8 million in Q2 2023.
  • Average Other financing activities over 4 years is $1.1 million, with a median of $800000.0 recorded in 2025.
  • The largest annual shift saw Other financing activities plummeted 855.66% in 2023 before it surged 1142.28% in 2024.
  • Oramed Pharmaceuticals' Other financing activities stood at $2.4 million in 2022, then soared by 186.85% to $6.7 million in 2023, then plummeted by 81.96% to $1.2 million in 2024, then skyrocketed by 87.83% to $2.3 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Other financing activities are $2.3 million (Q4 2025), $719000.0 (Q3 2025), and $800000.0 (Q2 2025).